氯(二甲基)膦 | 811-62-1

• 物质功能分类: 有机原料 - 有机膦化合物
• 分子结构分类: 有机化合物 - 有机磷化合物 - 烷基卤代膦
• 中文名称: 氯(二甲基)膦
• 中文别名: 二甲基氯化膦；二甲基氯化磷(磷应写作膦)
• 英文名称: chlorodimethylphosphine
• 英文别名: Dimethylchlorphosphin；chlordimethylphosphin；dimethyl chlorophosphine；chlorodimethylphosphane；Dimethylchlorphosphan；dimethylphosphine chloride；Chlordimethylphosphan；chloro(dimethyl)phosphane
• CAS: 811-62-1
• 化学式: C₂H₆ClP
• mdl: MFCD00013620
• 分子量: 96.4964
• InChiKey: ZLVVDNKTHWEIOG-UHFFFAOYSA-N

物化性质

• 熔点：
  -4-0℃
• 沸点：
  76-77°C
• 密度：
  1,22 g/cm3
• 闪点：
  -18°C
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与强氧化剂和热、水分直接接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  4
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 危险等级：
  4.2
• 安全说明：
  S16,S26,S36/37/39,S45
• 危险类别码：
  R17
• 危险品运输编号：
  UN 2845
• 包装等级：
  I
• 危险类别：
  4.2
• 储存条件：
  请将容器密封保存，并存放在阴凉、干燥的地方。

SDS

---

Section 1: Product Identification
Chemical Name: Dimethylchlorophosphine, min. 97%
CAS Registry Number: 811-62-1
Formula: (CH3)2PCl
EINECS Number: none
Chemical Family: organophosphine halide
Synonym: none

---

Section 2: Composition and Information on Ingredients
Ingredient CAS Number Percent ACGIH (TWA) OSHA (PEL)
Title Compound 811-62-1 100% no data no data

---

Section 3: Hazards Identification
Harmful by inhalation, in contact with skin and if swallowed. Material releases acid fumes. Inhalation of vapors
Emergency Overview:
may lead to headache and dizziness. Severe irritant to skin, eyes, and mucous membranes.
Primary Routes of Exposure: Ingestion, skin, inhalation
Eye Contact: Causes severe irritation of the eyes.
Skin Contact: Harmful in contact with skin. Causes severe irritation of the skin or thermal burns if ignited.
Harmful by inhalation. Inhalation may lead to headaches and dizziness. Causes severe irritation to the nose
Inhalation:
and mucous memb
Ingestion: Harmful if swallowed. May cause vomiting and diarrhea.
Acute Health Affects: Harmful by inhalation, in contact with skin and if swallowed.
Chronic Health Affects: No information available on long-term chronic effects.
NTP: No
IARC: No
OSHA: No

---

SECTION 4: First Aid Measures
Immediately flush the eyes with copious amounts of water for at least 10-15 minutes. A victim may need
Eye Exposure:
assistance in keeping their eye lids open. Get immediate medical attention.
Wash the affected area with water. Remove contaminated clothes if necessary. Seek medical assistance if
Skin Exposure:
irritation persists.
Remove the victim to fresh air. Closely monitor the victim for signs of respiratory problems, such as difficulty
Inhalation:
in breathing, coughing, wheezing, or pain. In such cases seek immediate medical assistance.
Seek medical attention immediately. Keep the victim calm. Give the victim water (only if conscious). Induce
Ingestion:
vomiting only if directed by medical personnel.

---

SECTION 5: Fire Fighting Measures
Flash Point: -1°F
Autoignition Temperature: no data
Explosion Limits: no data
Extinguishing Medium: carbon dioxide, dry powder or foam
Fire fighters should be equipped with a NIOSH approved positive pressure self-contained breathing apparatus
Special Fire Fighting Procedures:
and full protective clothing.
Hazardous Combustion and If involved in a fire this material may emit toxic organic fumes, hydrochloric acid fumes, and vapors of
Decomposion Products: phosphorus pentoxide.
Unusual Fire or Explosion Hazards: Spontaneously flammable in air, especially in contact with organic matter such as paper or cloth.

---

SECTION 6: Accidental Release Measures
Small spills can be mixed with sodium bicarbonate or other suitable absorbents. Spillage in areas not
adequately ventilation will require an evacuation of site. Material may spontaneously ignite. Emergency
Spill and Leak Procedures:
response teams will require self-contained breathing apparatus. Spill should be absorbed into vermiculite or
other suitable absorbent.

---

SECTION 7: Handling and Storage
Material is shipped in an all glass ampoule. Material must be handled and stored under an inert atmosphere
Handling and Storage:
of nitrogen or argon.

---

SECTION 8: Exposure Controls and Personal Protection
Eye Protection: Always wear approved safety glasses when handling a chemical substance in the laboratory.
Skin Protection: Wear protective clothing and gloves.
Ventilation: Material has a pungent odor. Always handle material in an efficient fume hood.
If ventilation is not available a respirator should be worn. The use of respirators requires a Respirator
Respirator:
Protection Program to be in compliance with 29 CFR 1910.134.
Ventilation: Material has a pungent odor. Always handle material in an efficient fume hood.
Additional Protection: Wear a full face shield, flame resistant lab apron and suitable gloves.

---

SECTION 9: Physical and Chemical Properties
Color and Form: colorless to pale yellow liq.
Molecular Weight: 96.50
Melting Point: no data
Boiling Point: 76-77°C
Vapor Pressure: no data
Specific Gravity: 1.22
Odor: pungent, acidic odor
Solubility in Water: reacts violently with water

---

SECTION 10: Stability and Reactivity
Stability: air and moisture-sensitive liquid
Hazardous Polymerization: no hazardous polymerization
Conditions to Avoid: contact with air.
Incompatibility: water, air, oxidizing agents, alcohols, halogens and active metals
Decomposition Products: carbon dioxide, carbon monoxide, hydrogen chloride, organic fumes, and phosphorus pentoxide.

---

SECTION 11: Toxicological Information
RTECS Data: No information available in the RTECS files.
Carcinogenic Effects: No data available
Mutagenic Effects: No data available
Tetratogenic Effects: No data available

---

SECTION 12: Ecological Information
Ecological Information: No information available

---

SECTION 13: Disposal Considerations
Disposal: Dispose of according to local, state and federal regulations.

---

SECTION 14: Transportation
Shipping Name (CFR): Pyrophoric liquids, Organic, N.O.S.
Hazard Class (CFR): 4.2
Additional Hazard Class (CFR): NA
Packaging Group (CFR): I
UN ID Number (CFR): UN# 2845
Shipping Name (IATA): Forbidden
Hazard Class (IATA): NA
Additional Hazard Class (IATA): NA
Packaging Group (IATA): NA
UN ID Number (IATA): UN# 2845

---

SECTION 15: Regulatory Information
TSCA: Not listed in the TSCA inventory.
SARA (Title 313): Not reportable under SARA Title 313
Second Ingredient: none

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

类别：自燃物品

可燃性危险特性：

• 在空气中可自燃
• 火场释放有毒氯化物和磷氧化物烟雾

储运特性：

• 库房应保持低温、通风和干燥
• 密闭保存

灭火剂：

• 水、二氧化碳、泡沫或砂土

反应信息

• 作为反应物：
  描述：

  氯(二甲基)膦 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 以100%的产率得到二甲基磷化氢
  参考文献：
  名称：

  Bond Activation in Iron(II) and Nickel(II) Complexes of Polypodal Phosphanes

  摘要：

  一种由吡啶衍生的四膦配体（给体组：NP₄）已被发现能够经历非常特异的C-P键裂解反应，从而产生一个具有NP₃给体组的配体。在适当条件下，该反应可以被逆转，原始的NP₄配体可以再生。为了研究这种反应的机制，制备了NP₃给体配体C₅H₃N[CMe(CH₂PMe₂)₂][CMe₂(CH₂PMe₂)]（11），并且通过Fe(BF₄)₂・6H₂O生成了其铁（II）配合物4，其中甲基二乙基膦酸酯（7）作为额外的单齿配体。配体11除了具有NP₃给体组外，还有一个与铁中心紧密接触的甲基基团，类似于一个Agostic M・ ・ ・H-C相互作用。根据铁（II）盐的化学计量比，会形成一个副产物15，该副产物具有一个二乙基膦配体，而不是与铁（II）配位的膦酸酯7。尽管试图去脱质子化金属配位的甲基基团未成功，但该反应被证明发生在另一个类似于4的替代配合物（18）中，该替代配合物具有三甲基膦配体，而不是膦酸酯7。配合物15与CO的反应产生了两种不同的产物，两者均通过单晶X射线衍射进行了表征。其中一种（19）是三膦配体11的二羰基铁（II）配合物，另一种（3）是四膦C₅H₃N[CMe(CH₂PMe₂)₂]₂（1）的羰基铁（II）配合物。这表明所涉及的C-P键形成可能是一种分子间机制。

  DOI：

  10.1515/znb-2010-0304
• 作为产物：
  描述：

  1,1,2,2-四甲基-二膦 在 二苯基氯化膦 作用下， 反应 2.0h， 以81%的产率得到氯(二甲基)膦
  参考文献：
  名称：

  核磁共振和核磁共振分析

  摘要：

  通过使四有机二膦与氯二苯基或二氯苯基膦反应，制备了一系列的二正烷基和正烷基芳基氯膦，并通过31 P和13 C NMR光谱进行了表征。

  DOI：

  10.1016/0022-328x(86)80520-4
• 作为试剂：
  描述：

  六氟-2-丁炔 在 氯(二甲基)膦 作用下， 生成 1,1,1,4,4,4-六氟-2-氯-2-丁烯
  参考文献：
  名称：

  Some reactions of hexafluorobutyne-2 with phosphines and amines

  摘要：

  已经进一步研究了加成反应R2EX + CF3C≡CCF3 → R2EC(CF3)=C(CF3)X（其中E = P和N）；从（C2H5）2PH，（CF3）2PH，（C6H5）2P—P（C6H5）2和（CH3）2NCl中获得了1:1加合物，但未从（CH3）2PCl或（CH3）2P—P（CH3）2中获得。 （CF3）2PH也会产生2:1加合物。 三苯基膦使丁炔在-78°时聚合。 三甲胺也发生类似但较慢的反应。 在水的存在下，三甲胺和丁炔生成双（丁烯基）醚顺，反式（CF3CH=CCF3）2O作为主要产物。

  DOI：

  10.1139/v67-468

文献信息

• Condensation Reactions of Chlorophosphanes with Chalcogenides
  作者：Sivathmeehan Yogendra、Saurabh S. Chitnis、Felix Hennersdorf、Michael Bodensteiner、Roland Fischer、Neil Burford、Jan J. Weigand

  DOI：10.1021/acs.inorgchem.5b02723

  日期：2016.2.15

  synthesis for diphosphane monochalcogenides (1Ch(R)) and their constitutional isomers, diphosphanylchalcoganes (2Ch(R)), was developed, featuring a condensation reaction between chlorophosphanes (R2PCl) and sodium chalcogenides (Na2Ch, Ch = S, Se, (Te)). The optimized protocol selectively yields either 1Ch(R) (R2(Ch)PPR2) or 2Ch(R) (Ch(PR2)2) depending upon the steric demand of the substituents R. Reaction

  开发了一种高产率且易于合成的二膦烷单硫属化合物（1 Ch （R））及其结构异构体二膦酰二氯烷（2 Ch （R）），其特征是氯膦（R 2 PCl）与硫属元素化钠（Na 2 Ch，Ch = S，Se，（Te））。优化的协议有选择地产生1 Ch （R）（R 2（Ch）PPR 2）或2 Ch （R）（Ch（PR 2）2）取决于取代基R的空间需求。提出了与不同反应结果一致的反应途径。中的应用1章（R）和2章（R）作为一类有趣的配体的示例性地由选定的过渡金属络合物的制备证明。
• NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF
  申请人：SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.

  公开号：US20190010153A1

  公开（公告）日：2019-01-10

  The present invention discloses a nitrogen-containing fused heterocyclic compound, as well as a preparation method, intermediate, composition and application thereof. The nitrogen-containing fused heterocyclic compound of the present invention as represented by formula (I), as well as the pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, metabolite or drug precursor thereof, exhibit a high selectivity and a high inhibitory activity with respect to CDK4 and CDK6 at a molecular level, an excellent inhibitory activity with respect to breast cancer cells at a cellular level, and significant inhibition of tumor cell proliferation associated with cyclin-dependent kinase activity at an animal level. The invention also exhibits a good stability with respect to human or mouse liver microsomes without significant inhibition of metabolic enzymes, good in vivo absorption in mice and rats, a high bioavailability and good druggability.

  本发明公开了一种含氮融合杂环化合物，以及其制备方法、中间体、组合物和应用。本发明的含氮融合杂环化合物如公式(I)所示，以及其药学上可接受的盐、对映体、二对映体、互变异构体、溶剂合物、代谢物或药物前体，在分子水平上对CDK4和CDK6表现出高选择性和高抑制活性，在细胞水平上对乳腺癌细胞表现出优异的抑制活性，并在动物水平上显著抑制与细胞周期依赖性激酶活性相关的肿瘤细胞增殖。该发明还在人类或小鼠肝微粒体中表现出良好的稳定性，没有显著抑制代谢酶，对小鼠和大鼠体内吸收良好，具有高生物利用度和良好的药物可用性。
• Coordination Behavior and Reactivity of α‐Heterosubstituted Trimethylsilylalkynes at Titano‐ and Zirconocene
  作者：Kai Altenburger、Wolfgang Baumann、Anke Spannenberg、Perdita Arndt、Uwe Rosenthal

  DOI：10.1002/ejic.201402851

  日期：2014.12

  The coordination behavior of the α-donor-atom-substituted (trimethylsilyl)alkynes OC4H8N–C≡C–SiMe3 (2), EtO–C≡C–SiMe3 (3), and Me2P–C≡C–SiMe3 (4) towards group 4 metallocene generators [Cp2Ti(η2-btmsa)] (1a), [Cp2Zr(py)(η2-btmsa)] (1b), and [Cp*2Ti(η2-btmsa)] (1c) [Cp = η5-cyclopentadienyl; btmsa = bis(trimethylsilyl)acetylene; py = pyridine; Cp* = η5-pentamethylcyclopentadienyl] was investigated.

  α-供体-原子取代的（三甲基甲硅烷基）炔烃 OC4H8N-C≡C-SiMe3 (2)、EtO-C≡C-SiMe3 (3) 和 Me2P-C≡C-SiMe3 (4) 的配位行为第 4 组茂金属发生器 [Cp2Ti(η2-btmsa)] (1a)、[Cp2Zr(py)(η2-btmsa)] (1b) 和 [Cp*2Ti(η2-btmsa)] (1c) [Cp = η5-环戊二烯基；btmsa = 双（三甲基甲硅烷基）乙炔；py = 吡啶；研究了 Cp* = η5-五甲基环戊二烯基]。通过使用 1a 和 1b，获得了炔烃 2 的金属环丙烯，炔烃 3 的钛环戊二烯和炔烃 4 的二聚体稳定的金属环丙烯。使用空间要求高的茂金属 1c 导致获得的炔烃 3 和 4 的单体金属环丙烯活性。也探索了对 CO2 和丙酮的影响，从而导致金属呋喃酮和金属二氢呋喃的区域选择性形成。
• Synthesis of Cationic R₂P₅⁺Cages and Subsequent Chalcogenation Reactions
  作者：Michael H. Holthausen、Alexander Hepp、Jan J. Weigand

  DOI：10.1002/chem.201204337

  日期：2013.7.22

  Cationic R2P5+ cage compounds (1+) have been synthesized by the stoichiometric reaction of R2PCl, GaCl3 and P4. The reaction conditions depend on the substituent R. Alkyl‐substituted derivatives (1 a–1 d[GaCl4]) are best synthesized under solvent‐free conditions, whereas aryl‐substituted derivatives (1 e–1 h[GaCl4]) are formed in C6H5F. All compounds have been prepared on a multi‐gram scale in good

  阳离子R 2 P 5 +笼型化合物（1 +）是通过R 2 PC1，GaCl 3和P 4的化学计量反应合成的。反应条件取决于取代基R。烷基取代的衍生物（1 a – 1 d [GaCl 4 ]）最好在无溶剂条件下合成，而芳基取代的衍生物（1 e – 1 h [GaCl 4 ]）则最好。在C 6 H 5中形成F.所有化合物都以好几克的量级以良好至极好的收率制备，并已充分表征，重点是溶液和单晶结构测定中的31 P NMR光谱。阳离子的后续chalcogenation反应- [R 2 P 5 +（1一+，图1e +）和三阳离子博士6 P 7 3+（3 3+）与元素硫（α-S 8）或灰色硒（Se灰色），得到一系列独特的多磷-硫属阳离子（4 a +，4 e +，5 a +，6 2+和7 2+），具有正三环烷型分子结构。提出了对31 P 1 H}和77 Se NMR光谱参数的深入研究，并详细研究了取代模式与观察到的结构特征之间的相关性。
• [EN] GOLD COMPOUNDS AND THEIR USE IN THERAPY<br/>[FR] COMPOSÉS D'OR ET LEUR UTILISATION DANS LE CADRE D'UNE THÉRAPIE
  申请人：AUSPHERIX LTD

  公开号：WO2018220171A1

  公开（公告）日：2018-12-06

  Compound of formula (I) and pharmaceutically acceptable salts and solvates thereof are described, wherein: Px selected from (P1), (P2) or (P3); The compounds are useful in the prevention or treatment of a bacterial infection.

  描述了化合物的公式（I）及其药用可接受的盐和溶剂化合物，其中：Px选自（P1）、（P2）或（P3）；这些化合物在预防或治疗细菌感染方面是有用的。

表征谱图